Mostra i principali dati dell'item
Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?
dc.creator | Ntelis K., Bogdanos D., Dimitroulas T., Sakkas L., Daoussis D. | en |
dc.date.accessioned | 2023-01-31T09:40:50Z | |
dc.date.available | 2023-01-31T09:40:50Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1007/s11926-019-0815-z | |
dc.identifier.issn | 15233774 | |
dc.identifier.uri | http://hdl.handle.net/11615/77337 | |
dc.description.abstract | Purpose of Review: Platelets are no longer recognized solely as cell fragments regulating hemostasis. They have pleiotropic functions and they are linked directly or indirectly with the three cornerstones of systemic sclerosis (SSc): vasculopathy, autoimmunity, and fibrosis. In this review, we summarize the current knowledge on the potential role of platelets in the pathogenesis of SSc. Recent Findings: Experimental evidence suggests that vasculopathy, a universal and early finding in SSc, may activate platelets which subsequently release several profibrotic mediators such as serotonin and transforming growth factor β (TGFβ). Platelets may also cross-react with the endothelium leading to the release of molecules, such as thymic stromal lymphopoietin (TSLP), that may trigger fibrosis or sustain vascular damage. Finally, activated platelets express CD40L and provide costimulatory help to B cells, something that may facilitate the breach in immune tolerance. Summary: Preclinical studies point to the direction that platelets are actively involved in SSc pathogenesis. Targeting platelets may be an attractive therapeutic approach in SSc. © 2019, Springer Science+Business Media, LLC, part of Springer Nature. | en |
dc.language.iso | en | en |
dc.source | Current Rheumatology Reports | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062401637&doi=10.1007%2fs11926-019-0815-z&partnerID=40&md5=c2e2d7aec33d3ced4e9eda4370999e50 | |
dc.subject | acetylsalicylic acid | en |
dc.subject | CD40 ligand | en |
dc.subject | clopidogrel | en |
dc.subject | connective tissue growth factor | en |
dc.subject | cytokine | en |
dc.subject | dipyridamole | en |
dc.subject | high mobility group B1 protein | en |
dc.subject | hydroxychloroquine | en |
dc.subject | ifetroban | en |
dc.subject | iloprost | en |
dc.subject | placebo | en |
dc.subject | platelet derived growth factor | en |
dc.subject | protein VEGF165b | en |
dc.subject | riociguat | en |
dc.subject | serotonin | en |
dc.subject | terguride | en |
dc.subject | thymic stromal lymphopoietin | en |
dc.subject | toll like receptor 4 | en |
dc.subject | transforming growth factor beta | en |
dc.subject | tumor necrosis factor ligand superfamily member 12 | en |
dc.subject | unclassified drug | en |
dc.subject | vasculotropin | en |
dc.subject | transforming growth factor beta | en |
dc.subject | vasculotropin A | en |
dc.subject | antigen expression | en |
dc.subject | autoimmunity | en |
dc.subject | B lymphocyte | en |
dc.subject | blood vessel injury | en |
dc.subject | controlled clinical trial (topic) | en |
dc.subject | cross reaction | en |
dc.subject | cytokine release | en |
dc.subject | early diagnosis | en |
dc.subject | finger ulcer | en |
dc.subject | human | en |
dc.subject | immunological tolerance | en |
dc.subject | multicenter study (topic) | en |
dc.subject | pathogenesis | en |
dc.subject | phase 2 clinical trial (topic) | en |
dc.subject | phase 3 clinical trial (topic) | en |
dc.subject | pulmonary hypertension | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | Review | en |
dc.subject | serotonin release | en |
dc.subject | systemic sclerosis | en |
dc.subject | thrombocyte activation | en |
dc.subject | vascular disease | en |
dc.subject | vascular endothelium | en |
dc.subject | vascular fibrosis | en |
dc.subject | autoimmunity | en |
dc.subject | blood | en |
dc.subject | fibrosis | en |
dc.subject | inflammation | en |
dc.subject | physiology | en |
dc.subject | systemic sclerosis | en |
dc.subject | thrombocyte | en |
dc.subject | Autoimmunity | en |
dc.subject | Blood Platelets | en |
dc.subject | Fibrosis | en |
dc.subject | Humans | en |
dc.subject | Inflammation | en |
dc.subject | Scleroderma, Systemic | en |
dc.subject | Transforming Growth Factor beta | en |
dc.subject | Vascular Endothelial Growth Factor A | en |
dc.subject | Current Medicine Group LLC 1 | en |
dc.title | Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis? | en |
dc.type | other | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |